Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers

Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers

The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6-91.4% enzyme inhibition and thus greatly reducing gastric lipolysis o...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of physiology: Gastrointestinal and liver physiology 2001-07, Vol.44 (1), p.G16-G28
Hauptverfasser: CARRIERE, Frederic, RENOU, Christophe, BEGLINGER, Christoph, HADVARY, Paul, VERGER, Robert, LAUGIER, René, RANSAC, Stéphane, LOPEZ, Veronique, DE CARO, Josiane, FERRATO, Francine, DE CARO, Alain, FLEURY, André, SANWALD-DUCRAY, Patricia, LENGSFELD, Hans
Format: Artikel
Sprache:eng
Schlagworte:
Biological and medical sciences
Clinical trials
Drug therapy
General and cellular metabolism. Vitamins
Medical sciences
Obesity
Pancreas
Pharmacology. Drug treatments
Weight control
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The inhibition of digestive lipases by the antiobesity drug Orlistat along with lipolysis levels and fecal fat excretion were measured in healthy humans. Orlistat was found to be a powerful gastric lipase inhibitor, achieving 46.6-91.4% enzyme inhibition and thus greatly reducing gastric lipolysis of solid and liquid meals (11-33% of respective controls).
ISSN:0193-1857
1522-1547